Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DC1I
|
|||
| Former ID |
DIB001162
|
|||
| Drug Name |
RG-7356
|
|||
| Synonyms |
RO-5429083; AR-001 series, ARIUS; ARH460-16-2; ChARH460-16-2; H460-16-2; MuARH460-16-2; Anti-CD44 antibody (cancer), ARIUS; Anti-CD44 mAb (cancer), Roche; Chimeric ARH460-16-2-IgG1; Chimeric ARH460-16-2-IgG2; (ch)ARH460-16-2-IgG1; (ch)ARH460-16-2-IgG2
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Discontinued in Phase 1 | [1] | |
| Company |
ARIUS Research Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hyaluronic acid receptor (LYVE1) | Target Info | . | [2] |
| Reactome | Hyaluronan uptake and degradation | |||
| WikiPathways | Glycosaminoglycan metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034685) | |||
| REF 2 | Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies. MAbs. 2014 Mar-Apr;6(2):567-75. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.